LAB/B: Q1 2025 saw robust EBITDA and EPS growth, with strong cash flow and margin gains

About this update from Genomma Lab Internacional Sab De Cv Class B

Genomma Lab posted 5.0% net sales growth and 12.0% EBITDA increase in Q1 2025, with strong free cash flow and margin expansion, despite US and Argentina headwinds. Management targets low-teen sales growth and a 24% EBITDA margin mid-term. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B